Education
About Us
Working with TipRanks
Follow Us
Mural Oncology Plc (MURA)
NASDAQ:MURA
Gemcitabine, Pembrolizumab, Pegylated Liposomal Doxorubicin (Pld), Paclitaxel, Topotecan, Nemvaleukin And Pembrolizumab Combination, Nemvaleukin
Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, Primary Peritoneal Cancer
Phase III
Terminated
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Oct 13, 2021
―
Pembrolizumab, Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing
Cutaneous Melanoma, Mucosal Melanoma
Phase II
Terminated
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
Apr 01, 2021
―
Alks 4230, Alks 4230 + Pembrolizumab
Advanced Solid Tumors
Phase I/II
Completed
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Jun 01, 2016
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mural Oncology Plc (MURA) have in its pipeline
MURA is currently developing the following drugs: Gemcitabine, Pembrolizumab, Pegylated Liposomal Doxorubicin (Pld), Paclitaxel, Topotecan, Nemvaleukin And Pembrolizumab Combination, Nemvaleukin, Pembrolizumab, Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing, Alks 4230, Alks 4230 + Pembrolizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.